Creative Planning’s BridgeBio Pharma BBIO Stock Holding History

Creative Planning’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.6M	Sell	115,511 -4,150	-3%	-$291K	0.01%	992
2026 Q1	$8.89M	Buy	119,661 +9,018	+8%	+$654K	0.01%	775
2025 Q4	$8.46M	Buy	110,643 +16,787	+18%	+$1.1M	0.01%	690
2025 Q3	$4.87M	Buy	93,856 +18,568	+25%	+$906K	﹤0.01%	902
2025 Q2	$3.25M	Buy	75,288 +13,924	+23%	+$506K	﹤0.01%	985
2025 Q1	$2.12M	Buy	61,364 +17,433	+40%	+$588K	﹤0.01%	1136
2024 Q4	$1.21M	Buy	43,931 +12,667	+41%	+$327K	﹤0.01%	1499
2024 Q3	$772K	Buy	+31,264	New	+$821K	﹤0.01%	1731
2024 Q1	–	Sell	-5,033	Closed	-$203K	–	2928
2023 Q4	$203K	Buy	+5,033	New	+$151K	﹤0.01%	2419

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Creative Planning's BBIO Position: Q2 2026 in Review

Creative Planning reduced its BridgeBio Pharma (BBIO) stake by 3.5% in Q2 2026, selling an estimated $291K and leaving 115,511 shares worth $8.6M. The position accounts for 0.01% of the portfolio, ranked #992.

Creative Planning first reported a position in BBIO in Q4 2023 and has held it in 9 quarters since. The position peaked at $8.89M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Creative Planning held 115,511 shares of BridgeBio Pharma worth $8.6M as of Q2 2026.
Creative Planning sold 4,150 BridgeBio Pharma shares in Q2 2026, an estimated $291K.
BridgeBio Pharma made up 0.01% of Creative Planning's portfolio in Q2 2026, its #992 holding.
Creative Planning first reported a position in BridgeBio Pharma in Q4 2023 and has held it in 9 quarters since.
Creative Planning's BridgeBio Pharma position peaked at $8.89M in Q1 2026.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.